- The USPTO issues U.S. Patent No. 9,675,641 to Fate Therapeutics (NASDAQ:FATE -1.3%) covering the use of prostaglandins as viral transduction enhancers for the genetic modification of CD34+ hematopoietic cells. The patent, effective until 2029, is owned by the Indiana University Research and Technology Corporation and is licensed exclusively to Fate in all fields.
Fate lands new U.S. patent covering gene therapy
Recommended For You
More Trending News
About FATE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
FATE | - | - |
Fate Therapeutics, Inc. |